In the follow up of the recent High Level Nuclear Round Table with Commissioner Mariya Gabriel on 13 February 2023, obstacles for a translation of research into a broader use of theranostic radiopharmaceuticals in clinical practice, as well as further expected developments in radiotheranostics will be discussed and identified.
- cancer | medical research
- -
- Ispra, Italy
Programme
- 27 Apr 2023,
08:30 AM - 09:15 AM CESTRegistration & coffee - 09:15 AM - 09:50 AM CESTWelcome and Introduction
EU Commissioner Mariya Gabriel
JRC DDG Bernard Magenhann
Representative of Swedish Presidency (t.b.c.)
Group photo - 09:50 AM - 12:20 PM CESTSession 1 – Radiotheranostics: radionuclide-based therapy and companion diagnostics
9:50-10:20 - Principles of and clinical experiences with peptide receptor radio-therapy of neuroendocrine tumours and radio-ligand therapy of advanced prostate cancer (Richard P. Baum)
10:20-10:50 - Results of 177Lu-PSMA-617 phase II prospective trial IRST-185 and role of androgen receptor amplification in PSMA-RLT (Giovanni Paganelli)
10:50-11:05 - mCRPC patients receiving 225Ac-PSMA-617 therapy in the post–androgen deprivation therapy setting (Alfred Morgenstern)
11:05-11:20 - Coffee
11:20-11:50 - The role of Centers of Excellence and multidisciplinary tumor boards for quality treatment of NET (Marianne Pavel)
11:50-12:20 - Radioligand therapy of metastatic prostate cancer– the oncologists view (Silke Gillessen) - 12:20 PM - 01:00 PM CESTSession 2 – The cancer patients’ view
Erik Briers (Europa Uomo), Anna Nilsson (care giver), Luciano Licciardello and Barbara Picutti (Associazione Pazienti con Tumori Neuroendocrini)
- 01:00 PM - 03:00 PM CESTSession 3 – Radiotheranostics: innovations and challenges
13:00-13:30 - Exploiting radiobiological effects of targeted radionuclide therapy (Jean-Pierre Pouget)
13:30-14:30 - Buffet Lunch
14:30-15:00 - New developments and challenges facing clinical translation of radiotheranostics (KenHerrmann) - 03:00 PM - 05:00 PM CESTSession 4 – Translating radiotheranostics into clinical practice
All & in addition Odile Jaume (ICPO), Heinz-Peter Schlemmer (EACS), Stefano Fanti (University of Bologna), Konrade von Bremen (Nuclear Medicine Europe), Ulla Engelmann (JRC)
15:00-15:50 - Identification of critical factors, potential roadblocks and the relevant stakeholders
15:50-16:00 - Coffee
16:00-17:00 - How to tackle roadblocks - 05:00 PM - 05:30 PM CESTWrap-up & recommendations
- 05:45 PM - 06:00 PM CESTTransport to the hotel or airport
Practical information
- When
- -
- Where
- Joint Research CentreIspra, Italy
- Languages
- English
Description
The Workshop will address the clinical potential of radiotheranostics in cancer diagnosis and treatment, focusing on the examples of neuroendocrine tumours and advanced prostate cancer, two indications for which now approved radiopharmaceuticals exist. The workshop attempts to identify obstacles for a broader use of such radiopharmaceuticals in clinical practice and discusses possible ways to overcome them.
The workshop will be held as a hybrid event and can also be followed via Webex.
Attendance
Please note that for the attendance on site only a limited hotel capacity is available and the requests are processed on a first come, first served basis.
Attending the workshop is free of charge, but no reimbursement for travel and hotel costs is granted. The deadline for registration is 31st March 2023.
How to register
Should you be interested in participating, please contact the meeting assistants at JRC-F2-MEETINGS@ec.europa.eu for further information and details on the registration procedure, indicating whether you have a preference to attend on-site in Ispra or remotely via Webex.